Patient Guide: A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 133 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT03600883
Status: ACTIVE_NOT_RECRUITING
Condition: KRAS p.G12C Mutant Advanced Solid Tumors
Phase: PHASE1, PHASE2

Where You Can Participate

This study is available at 133 locations across the country.

Top locations include:
  • • Duarte, California
  • • Los Angeles, California
  • • San Francisco, California
  • • And 130 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100) - Join Clinical Trial NCTNCT03600883

How to Join This Clinical Trial - NCTNCT03600883

Learn how to participate in this PHASE1, PHASE2 trial studying an investigational therapy for KRAS p.G12C Mutant Advanced Solid Tumors. Current status: ACTIVE_NOT_RECRUITING.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with KRAS p.G12C Mutant Advanced Solid Tumors. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
KRAS p.G12C Mutant Advanced Solid Tumors
Treatment Being Tested
Investigational treatment
Study Phase
PHASE1, PHASE2 - Safety and effectiveness study
Enrollment Status
ACTIVE_NOT_RECRUITING
Study Identifier
NCTNCT03600883 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 133 locations. Find a study site near you:

Clinical Research Site

Duarte, California 91010 - United States

Status: Contact for availability

Clinical Research Site

Los Angeles, California 90095 - United States

Status: Contact for availability

Clinical Research Site

San Francisco, California 94115 - United States

Status: Contact for availability

Clinical Research Site

Santa Monica, California 90403 - United States

Status: Contact for availability

Clinical Research Site

Denver, Colorado 80218 - United States

Status: Contact for availability

Clinical Research Site

Denver, Colorado 80218 - United States

Status: Contact for availability

Clinical Research Site

New Haven, Connecticut 06510 - United States

Status: Contact for availability

Clinical Research Site

Newark, Delaware 19713 - United States

Status: Contact for availability

Clinical Research Site

Gainesville, Florida 32610 - United States

Status: Contact for availability

Clinical Research Site

Orlando, Florida 32804 - United States

Status: Contact for availability

And 123 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE1, PHASE2 clinical trial for KRAS p.G12C Mutant Advanced Solid Tumors:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships